Další formáty:
BibTeX
LaTeX
RIS
@proceedings{2327137, author = {Obermannová, Radka and Selingerová, Iveta and Demlová, Regina and Valík, Dalibor and Zdražilová Dubská, Lenka and Kiss, Igor}, doi = {http://dx.doi.org/10.1016/j.annonc.2023.04.432}, keywords = {COVID-19; Solid cancer; multicentric trial;}, language = {eng}, title = {CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors}, url = {https://www.sciencedirect.com/science/article/pii/S0923753423005744?via%3Dihub}, year = {2023} }
TY - CONF ID - 2327137 AU - Obermannová, Radka - Selingerová, Iveta - Demlová, Regina - Valík, Dalibor - Zdražilová Dubská, Lenka - Kiss, Igor PY - 2023 TI - CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors KW - COVID-19 KW - Solid cancer KW - multicentric trial; UR - https://www.sciencedirect.com/science/article/pii/S0923753423005744?via%3Dihub N2 - Solid cancer patients are at high risk of a more severe course of COVID-19, especially those undergoing active anti-cancer therapy causing immunosuppression. Vaccination is still the only option to prevent serious events associated with SARS-CoV-2 infection. We aim to assess adverse effects, efficacy, and immune response against SARS-CoV-2 in cancer patients, focusing on comparison with healthy volunteers and possible interfering therapy. ER -
OBERMANNOVÁ, Radka, Iveta SELINGEROVÁ, Regina DEMLOVÁ, Dalibor VALÍK, Lenka ZDRAŽILOVÁ DUBSKÁ a Igor KISS. \textit{CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors}. 2023. Dostupné z: https://dx.doi.org/10.1016/j.annonc.2023.04.432.
|